• Product Name17-AAG (Tanespimycin)
• Brief DescriptionInhibitors
• Purification99.83%
• Biological Activity17-AAG (Tanespimycin) is a potent HSP90 inhibitor with IC50 of 5 nM, having a 100-fold higher binding affinity for HSP90 derived from tumour cells than HSP90 from normal cells. Phase 2.
• Target NameHSP inhibitor
• CAS No. 75747-14-7
• Calculated MW 585.69
• Formulation C31H43N3O8
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O |r,c:7,23,t:15,21,34|
  Pathways:Cytoskeletal Signaling; Metabolism
  Receptor:HSP90
  Boling pt:
  Melting pt:
  Solubility:DMSO:100 mg/mL (170.73 mM)Ethanol:5 mg/mL (8.53 mM)Water:<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Kamal A, et al. Nature, 2003, 425(6956), 407-410.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting